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Abstract
Mutations of the gene encoding the tumor suppressor protein p53 are the most common molecular alterations of cancer
cells found in about half of all human tumors. Mutations which cluster in well-defined hot spots change the structure of the
protein thus affecting its ability to bind to DNA. Post-translational modifications, primarily phosphorylation, might also
influence how p53 binds to DNA or folds to its active tetrameric form. However, the lack of appropriate biochemical
markers to characterize the status of phosphorylation in different cell types and in cells at different stages of tumor
progression has prohibited such investigations. To generate a sensitive and phosphorylation-specific monoclonal antibody
(mAb), we chemically synthesized the C-terminal 23 amino acid stretch of human p53 in a double-phosphorylated form. The
peptide 371^393, carrying phosphate groups on Ser378 and Ser392, was co-synthesized with a turn-inducing spacer and
peptide 31D, an immunodominant T-helper cell epitope in mice of the H-2k haplotype. After immunization and fusion of
splenocytes with myeloma cells, a number of mAbs were obtained, from which mAb p53-18 emerged as a highly sensitive
reagent. By enzyme-linked immunosorbent assay, p53-18, a mAb of the IgM isotype, recognized phosphorylated p53,
expressed in insect cells infected with a recombinant baculovirus but not p53 expressed in Escherichia coli. Moreover, murine
p53 from insect cells could be immune purified with mAb p53-18. Mass spectrometry following tryptic digestion of the
purified protein and liquid chromatography of the fragments verified the presence of phosphate groups at both Ser375 and
Ser389. From the corresponding human protein fragments, mAb p53-18 bound to the immunizing peptide phosphorylated
on Ser378 and on Ser392, but failed to cross-react with the unphosphorylated peptide, or peptides phosphorylated
individually on either Ser378 or Ser392. The binding to the unphosphorylated peptide could be restored, however, if the
peptide conformation was stabilized to that of an K-helix. The immunogenic nature of the multiphosphorylated C-terminus
of p53 is indicated by the finding that human sera, mostly from cancer patients, preferentially recognized the double-
phosphorylated peptide over the monophosphorylated or unphosphorylated analogs. Antibody p53-18 appears to be a
highly useful biochemical marker to detect low levels of p53 protein in different tissues, and to be a key tool to characterize
the phosphorylation status of the C-terminus of p53 protein originated from various sources. 0167-4889 / 98 / $ ^ see front
matter ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
The tumor suppressor protein p53 is considered a
guardian of the genome [1]. The p53 gene encodes a
nuclear phosphoprotein that is altered by mutation
or deletion in about 50% of human tumors [2]. p53
protein can be divided into ¢ve distinct regions. The
transactivation domain covers the ¢rst 42 amino acid
stretch. This region mediates the transcriptional ac-
tivity of p53, which is directly correlated to its ability
to suppress cell growth [3]. The next domain, the
DNA-binding domain (located between amino acids
96 and 286), is responsible for sequence-speci¢c
DNA binding [4]. Recently, an additional functional
domain was identi¢ed on p53 between the transacti-
vation and the sequence-speci¢c DNA binding do-
mains. Walker and Levine [5] localized a region be-
tween amino acids 61 and 94 that is necessary for
e⁄cient growth suppression. The tetramerization do-
main (amino acids 319^360) of p53 interacts with
other p53 protein chains to form the biologically
active tetramer, as was shown by peptide mapping
[6]. In reality this is not a true tetramer, but a dimer
of dimers in which each chain contributes with a L-
pleated sheet and an K-helix [7^9]. The ¢fth domain
(basic domain) carries a highly positive charge and
interacts non-sequence speci¢cally with DNA. This
basic region is located at the C-terminus between
amino acids 363 and 386 [10,11]. p53 lacking the
last 30 amino acids at the C-terminal end exhibits
higher double stranded DNA-a⁄nity, suggesting a
negative regulation of speci¢c DNA binding by the
basic region [12,13], but this same truncation acti-
vates binding to damaged DNA structures [14,15].
Oligomerization is thought to be in£uenced by the
C-terminal region including the basic domain [16].
The £exible regions between the domains are in-
volved in conformational changes necessary for the
molecule’s regulatory e¡ects. Changes in the primary
or secondary structure of p53 results in protein var-
iants with altered biological characteristics.
As single point mutations modify p53’s structure
and function, post-translational modi¢cations are ex-
pected to interfere with transcriptional control as
strongly. The most prominent of these post-transla-
tional modi¢cations is the phosphorylation of p53.
Phosphorylation sites span the entire protein and
distinct phosphorylation sites are found in at least
three domains and in the £exible segments between
them. The importance of phosphorylation of p53 in
determining the biological role of the protein is being
increasingly appreciated [17,18]. It seems that the two
£exible domains, the N-terminal transactivation do-
main and the C-terminal basic domain, are the major
sites of protein kinase activity. Incidentally, these are
the regions of p53 that induce most of the anti-p53
autoantibodies in cancer patients [19].
The most useful reagents for the detection and
quanti¢cation of proteins secreted by cells or present
in tissues are monoclonal antibodies (mAbs). Indeed,
mAbs and polyclonal antibodies are the reagents of
choice to characterize the active or inactive status of
tumor suppressor p53 [20^23]. Speci¢c DNA binding
of p53 was greatly increased after saturation with an
antibody termed 421. This antibody blocked the C-
terminal non-speci¢c DNA-binding sites, favoring
the speci¢c DNA-binding of the middle region of
the protein [13]. Native p53 (wild-type or mutant)
in cell lines and tissues is a weak immunogen, prob-
ably because of the low level of protein expression.
Although a number of anti-p53 antibodies are avail-
able commercially, their applicability is often limited.
Lane and coworkers [24] conducted a thorough anal-
ysis of the epitope distribution of p53, and concluded
that in addition to the immunogenic N- and C-ter-
mini, very few new antigenic sites can be identi¢ed.
Based on their recommendation, new approaches will
have to be employed to identify novel immunological
reagents to p53. According to these authors, immu-
nization with peptides may be the most productive
route to overcome the host restraints and to isolate
mAbs to hidden p53 epitopes.
Here we report the generation of a highly sensitive
mAb to p53 by using a double-phosphorylated pep-
tide immunogen corresponding to amino acids 371^
393 of the C-terminal basic domain of p53. In con-
ventional aqueous environments, mAb p53-18 was
highly speci¢c for phosphorylated Ser378 and
Ser392 at both the protein and the corresponding
peptide levels. When the peptide conformation was
changed during the assay procedure to that of an K-
helix, however, mAb p53-18 also detected the un-
phosphorylated p53 C-terminal fragment. The immu-
nodominance of the phosphorylated p53 C-terminus
is indicated by the fact that cancer patients’ sera
preferentially labeled the same sequence as mAb
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p53-18, i.e., the double-phosphorylated peptide anti-
gen.
2. Materials and methods
2.1. Synthetic peptides
Peptides were synthesized on Milligen 9050 and
Rainin PS3 automatic synthesizers using 9-£uorenyl-
methoxycarbonyl (Fmoc) amino acids according to
standard procedures [25]. Phosphoserine residues
were incorporated as Fmoc-Ser(PO3HBzl)-OH [26],
purchased from Novabiochem (San Diego, CA,
USA). Peptides and phosphopeptides were detached
from the solid support with tri£uoroacetic acid
(TFA), and they were puri¢ed by reversed-phase
high-performance liquid chromatography (RP-
HPLC) using an aqueous acetonitrile gradient elu-
tion system containing 0.1% TFA as an ion-pairing
reagent. The integrity of the peptides and phospho-
peptides was veri¢ed by mass spectroscopy. Table 1
lists the sequences of the synthetic peptides and Ta-
ble 2 demonstrates the methods used for their char-
acterization. Two sets of peptides were made. One of
them contained peptides of 23 amino acids long, and
the second set contained peptides of 33 amino acids
long (the peptides were extended to their N-termini).
The peptides were either unphosphorylated, con-
tained single phosphate groups on Ser378 or
Ser392, or phosphates on both serines.
2.2. Immunization
The 23-mer double-phosphorylated peptide was
co-synthesized with a turn inducing spacer (Gly^
Ala^Gly) and the immunodominant T-helper cell de-
terminant 31D of the rabies virus nucleoprotein [27]
in an orientation that placed the T-cell epitope to the
N-terminus and the B-cell epitope to the C-terminus.
Groups of 6-week-old female C3H/He mice were in-
oculated with 10 Wg of the tandem peptide mixed
with 50% complete Freund’s adjuvant in each hind
leg. Fourteen days later, the mice received a booster
immunization of 20 Wg in 50% incomplete Freund’s
adjuvant. Ten days after the booster immunization,
the mouse sera were screened and a third immuniza-
tion was applied, followed by fusion of splenocytes
with myeloma cells 5 days later using previously de-
scribed methods [28]. Hybridomas were grown in se-
lective medium, screened and subcloned according to
standard procedures [29]. High titer of mAbs were
produced as ascites upon injection of hybridoma cells
into immunode¢cient RAG-2 mice. The isotypes
were determined using the Calbiochem (San Diego,
CA, USA) isotyping kit according to the manufac-
turer’s speci¢cations.
2.3. A⁄nity puri¢cation of baculovirus expressed
murine p53
Ascites of mAb p53-18 was precipitated using sat-
urated ammonium sulfate and the pellet was dia-
lyzed against phosphate-bu¡ered saline (PBS) (pH
7.6) containing 0.1 M NaCl. The mAb was puri¢ed
by size-exclusion chromatography on a Sepharose S-
300 column and fractions 11^17 (7 ml each) contain-
ing IgM were collected and analyzed by sodium do-
decyl sulfate^polyacrylamide gel electrophoresis
(SDS^PAGE). Fractions 11^14 containing IgM im-
munoglobulin were pooled. Ten mg of puri¢ed mAb
p53-18 was coupled to 2 ml of CNBr-activated Se-
pharose 4B Fast Flow (Pharmacia, Uppsala, Swe-
den). Unreacted functional groups on the matrix
were blocked by incubation with 0.1 M Tris^HCl
bu¡er, pH 8.0. The column was washed several times
alternating with Tris^HCl bu¡er (pH 8.0) and ace-
tate bu¡er (pH 3.6). The source of murine p53 pro-
tein was a cellular extract of Sf9 insect cells infected
with recombinant baculovirus expressing murine
wild-type p53 generated by the Expression Vector
Facility of the Wistar Institute. Sf9 cells were col-
lected, lysed in PBS containing 0.1% NP-40 and cen-
trifuged at 12 000Ug for 15 min. The column was
equilibrated with PBS (pH 7.6) containing 0.1 M
NaCl. The supernatant containing soluble p53 was
loaded onto the p53-18 a⁄nity column followed by
washing with phosphate bu¡er and PBS to elute non-
speci¢cally bound proteins. Murine p53 protein was
recovered from the a⁄nity column by elution with
0.1 M glycine (pH 2.9), into tubes containing 1/10
fraction volume of 1 M Tris^HCl, pH 8.0. The pro-
tein composition of each fraction was evaluated us-
ing 12% SDS^PAGE in the presence of protein mo-
lecular mass markers and visualized with Coomassie
blue staining.
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2.4. Western blot
Fractions from the immunoa⁄nity puri¢cation of
murine p53 as well as p53 variants expressed in var-
ious cells (see Section 3 and legend to Fig. 3) were
also probed with mAb p53-18 by using conventional
Western blot techniques [29]. Brie£y, proteins and
protein fractions were applied to a 12% SDS^
PAGE gel and after electrophoresis were transferred
to nitrocellulose membranes. The membrane was
blocked with 5% fat-free milk dissolved in PBS con-
taining 0.01% Tween-20. After washings, the mem-
branes were incubated with various dilutions of the
antibody. 125I-Labeled (400 000 cpm/ml) goat anti-
mouse IgG was used as a secondary antibody in
PBS containing 0.01% Tween-20. Membranes were
washed extensively and autoradiography was per-
formed with X-Omat X-ray ¢lms (Kodak, Rochester,
NY, USA).
Table 2
Characterization of synthetic peptides
Peptide Retention time on RP-HPLC (min) Matrix-assisted laser desorption/ionization mass spectroscopy
calculated mass (Da) found (M+H)
p53 371^393; nP 23.2 2593 2592
p53 371^393; 378P 23.0 2673 2673
p53 371^393; 392P 23.3a 2673 2672
p53 371^393; 378P, 392P 23.3 2753 2754
p53 361^393; nP 23.4 3656 3657
p53 361^393; 378P 23.5 3736 3736
p53 371^393; 392P 23.4a 3736 3736
p53 371^393; 378P, 392P 23.9 3816 3819
aMeasured on a somewhat slower eluting column.
Table 1
Sequences of synthetic peptides
Amino acids marked with asterisks are phosphorylated.
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2.5. Recombinant p53 protein
Recombinant p53 cDNAs were cloned into the
bacterial expression vector pT5T encoding an addi-
tional N-terminal 6-histidine epitope tag. Recombi-
nant proteins were expressed in Escherichia coli
BL21. Bacteria were lysed in an extraction bu¡er
and bacterial DNA was degraded by addition of 50
Wg/ml of DNase I. The suspension was cleared by
centrifugation at 120 000Ug at 4‡C, and p53 protein
in the supernatant was puri¢ed over a metal-chelat-
ing column (Pharmacia, Piscataway, NJ, USA) ac-
cording to the instructions of the manufacturer.
2.6. Enzyme-linked immunosorbent assay (ELISA)
Direct ELISA was performed as described previ-
ously [30]. First the active dilution range of antibody
preparation was determined, and then the selectivity
of a given antibody dilution toward various peptide
antigens was assessed. Generally 40 ng^2.5 Wg pep-
tide antigens and 0.5 ng^1.2 Wg protein samples were
loaded in each well. Actual peptide concentrations
were determined by RP-HPLC [31]. Because mAb
p53-18 is an IgM subtype, the ELISA conditions
were modi¢ed as follows. The peptides were applied
to the plate and allowed to dry overnight. The plates
were washed with a PBS solution (pH 6.8) containing
0.04% Triton X-100. This solvent was used in all
consecutive steps. To look for conformational e¡ects,
the assay was repeated identically, except the pep-
tides were dissolved in tri£uoroethanol (TFE) instead
of water and dried to the ELISA plate overnight [32].
Sera of cancer patients and healthy controls were
screened for circulating anti-p53 autoantibodies us-
ing the same protocol. This time the washing bu¡er
contained 1 mg/ml of bovine serum albumin and the
secondary antibody was a sheep anti-human IgG.
The rest of the ELISA protocol remained un-
changed.
2.7. Liquid chromatography-coupled mass
spectroscopy (LC^MS)
The a⁄nity-puri¢ed mouse p53 protein was di-
gested with trypsin at 37‡C for 6 h in 50 mM ammo-
nium bicarbonate, pH 8.5. The reaction was halted
by lyophilization of the sample. The tryptic digest
was submitted to LC^MS as follows: RP-HPLC
was performed by using a Hewlett^Packard model
1100 binary system and a Vydac C18 narrow bore
column with 0.1% aqueous TFA and 0.1% TFA in
90% aqueous acetonitrile as solvents at 35‡C. A
1.25%/min gradient was applied with the system run-
ning at a 0.3 ml/min £ow rate. Peaks were recorded
at 214 nm. MS detection was achieved using a VG
Biotech BIO-Q triple quadrupole mass spectrometer
operating in the positive ion electrospray ionization
mode in the 250^950 m/z scan range, 46 V cone volt-
age at 80‡C. The instrument was calibrated with CsI
prior to the LC^MS.
3. Results
The double-phosphorylated 23-mer peptide was
co-synthesized with a sequence containing an immu-
nodominant T-helper cell epitope delineated from the
rabies virus nucleoprotein. This chimeric peptide
construct was injected into mice to generate mAbs.
An earlier application of this strategy using a B-cell
epitope of rabies virus has resulted in the production
of antibodies capable of providing protective immun-
ity against a lethal rabies virus challenge infection
[28]. After fusion of the spleen cells of mice immu-
nized with the p53-phosphopeptide construct, eight
hybridomas were selected. All of these clones recog-
nized the immunizing double-phosphorylated peptide
antigen strongly. The most promising mAb, p53-18
showed higher binding than antibodies from the oth-
er hybridomas. Antibody isotyping revealed that
mAb p53-18 was an IgM. IgMs are known to bind
to a number of unrelated proteins on ELISA. There-
fore, in all consecutive assays we used thorough
washing of the plates with 0.04% Triton X-100 in
PBS solution instead of blocking the plates with
horse serum or other proteins or mixtures of proteins
after application of the antigens.
Hybridoma cells secreting antibody p53-18 were
subcloned and the mAb was produced as ascites £uid
in RAG-2 mice. First, the antigen speci¢city of mAb
p53-18 was characterized by binding to the 23-mer
peptides. One Wg each of the four peptides, unphos-
phorylated, phosphorylated on Ser378, phosphory-
lated on Ser392 or phosphorylated on both Ser378
and Ser392 were tested against mAb p53-18 using
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serial dilutions of the ascites £uid ranging from 1:100
to 1:10 000 (Fig. 1). The double-phosphorylated pep-
tide was recognized at an ascites dilution as high as
1:2000. The antibody binding constantly increased
with decreasing dilution. None of the other three
peptides were recognized below a 1:500 antibody di-
lution, and the recognition of the double-phosphory-
lated peptide was considerably stronger than any of
the other three peptides in the entire antibody dilu-
tion range. If any distinction among the unphos-
phorylated and the two monophosphorylated pepti-
des is to be made, the Ser392 phosphorylated peptide
appeared to be slightly better recognized than the
other two variants. This experiment was repeated
with the four 33-mer peptides, and with a constant
dilution of the ascites £uid (1:200) with the antigen
load varying between 0.004 and 5 Wg. Again, only the
double-phosphorylated peptide bound appreciatively
to mAb p53-18 (data not shown).
After determining the peptide speci¢city of mAb
p53-18, we investigated whether binding of mAb
p53-18 was similarly dependent upon the presence
of phosphate groups at the p53 protein level. Two
p53 protein preparations were tested by direct
ELISA using a 1:200 dilution of the ascites £uid.
One of the p53 proteins (corresponding to the human
sequence) was expressed in E. coli, and is likely to be
unphosphorylated, or phosphorylated to a very low
degree. The other protein variant was expressed in
insect cells infected with mouse p53 baculovirus re-
combinant, and was expected to be highly phos-
phorylated. As a negative control, protein E7 of hu-
man papilloma virus (HPV)-16 was expressed by the
baculovirus system using identical conditions. From
the two p53 variants, the mAb recognized only the
phosphorylated protein (derived from insect cells),
and failed to bind to the unphosphorylated variant
(derived from E. coli) (Fig. 2). Actually, the mAb
binding to the phosphorylated protein exhibited
some ‘pro-zone’ binding behavior, indicating optimal
antigen^antibody interactions during these experi-
mental conditions. Positive binding was detected
with as little as 0.08 Wg antigen. It needs to be men-
tioned that some unspeci¢c binding to the E7 protein
was also observed, but this was well below the bind-
ing to p53 and without the ‘pro-zone’ binding char-
acteristics. Antibody p53-18 did not cross-react with
the unphosphorylated protein variant even when as
much as 0.3 Wg protein was loaded. For a positive
control, we used the commercially available antibody
421. It is considered that antibody 421 is a weak
reagent in ELISA. Nevertheless, in our hands using
identical assay conditions, the same E. coli expressed
p53 protein preparation (0.25 Wg and higher
amounts) was recognized by a 1:50 dilution of poly-
clonal antibody (pAb) 421 (Fig. 2). Antibody 421
binds to an unmodi¢ed (unphosphorylated and un-
glycosylated) epitope around Ser378 [33]. Our pep-
tide ELISA results supported this ¢nding, as we de-
tected low levels of 421 binding (at antibody dilution
of 1:20) to 1 Wg of the unphosphorylated 23-mer
peptide (OD = 0.25) and complete lack of antibody
421 binding to the Ser378 phosphorylated or double-
phosphorylated peptides (data not shown). Neverthe-
less, because of the low degree of 421 binding to the
Fig. 1. Binding of mAb p53-18 to synthetic peptides corre-
sponding to amino acids 371^393 of p53 protein. For these ex-
periments, 1 Wg amounts of the synthetic peptides were diluted
in water and were applied to ELISA plates. Plates were blocked
with Triton X-100 dissolved at a concentration of 0.04% in
PBS bu¡er, and the ascites £uid containing the antibody was
added in a series of dilutions ranging from 1:100 to 1:10 000.
The open triangles and dotted line represent the unphosphory-
lated peptide; the open circles and dashes represent the peptide
phosphorylated on Ser378; and the open squares and dots and
dashes represent the peptide phosphorylated on Ser392. The
closed symbols represent the double phosphorylated peptide;
closed triangles and solid line correspond to the 378P, 392P
peptide against mAb p53-18, and closed circles and randomly
staggered line correspond to the same peptide tested for binding
to an unrelated IgM control mAb.
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peptides, these results need to be treated with cau-
tion. In summary, the combined peptide and protein
ELISA data clearly show that mAb p53-18 recog-
nized p53 protein and its fragments regardless of
the species of origin (i.e., human or mouse), but
only if the C-terminus of the protein was phosphory-
lated.
In the next step, we characterized the ability of
mAb p53-18 to bind p53 on Western blot (Fig.
3A). The antibody bound to mouse p53 expressed
in insect cells infected with baculovirus, in a pattern
identical to that obtained by using another commer-
cially available mAb, antibody 240 (Fig. 3B). Anti-
body 240 recognizes an amino acid stretch around
residue 215, and labels p53 from many species, e.g.
human, mouse, rat, etc. [34]. Antibody p53-18 also
reacted with di¡erent forms of p53, including p53
MD (MI234, EG168) and p53 VD (AV135), mutants
of mouse p53 with amino acid exchanges within the
mutational hot spot domain (expressed by vaccinia
virus in infected cells). In addition, the antibody
cross-reacted with human wild-type p53 expressed
by adenovirus in 293 cells, yet it failed to label the
negative controls, such as insect cells infected with
baculovirus alone, human immunode¢ciency virus
gp160 expressed by vaccinia virus and rabies glyco-
protein expressed by adenovirus in 293 cells. Again,
Fig. 3. Binding of mAbs to di¡erent p53 protein preparations
on Western blot. Panel A corresponds to the blot developed
with mAb p53-18; panel B corresponds to an identical blot de-
veloped with mAb 240. The antigens are as follows: lane 1,
mouse p53 expressed by baculovirus in insect cells ; lane 2, in-
sect cell control infected with baculovirus alone; lane 3, p53 ex-
pressed by vaccinia virus in HeLa cells ; lanes 4 and 5, mutated
p53 variants: MD (MI234, EG168) and VD (AV135) expressed
by vaccinia virus; lane 6, human immunode¢ciency virus gp160
expressed by vaccinia virus; lane 7, human p53 expressed by
adenovirus in 293 cells ; lane 8, rabies glycoprotein expressed by
adenovirus in 293 cells. The molecular mass markers are at the
far right column.
Fig. 2. ELISA of phosphorylated and unphosphorylated p53
protein variants. Closed triangles and solid line represent p53
expressed by a recombinant baculovirus in insect cells against
mAb p53-18. Crosses and dotted lines represent the negative
control in which the unrelated E7 of HPV-16 protein was ex-
pressed by baculovirus and reacted against mAb p53-18. p53
expressed in E. coli is symbolized by circles. Closed circles and
dots and dashes correspond to E. coli expressed p53 against
mAb p53-18; open circles and dashes correspond to the same
protein preparation against antibody 421. For the experiments
with mAb p53-18 (IgM), the plates were blocked with Triton
X-100 after application of the antigens. Because pAb 421 is an
IgG isotype, the plate was blocked with horse serum according
to conventional ELISA protocols. The dilution of the ascites
£uid containing mAb p53-18 was 1:200, and the supernatant of
antibody 421 secreting cells was diluted to 1:50.
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the recognition pattern of mAb p53-18 was basically
identical to that of mAb 240 to all positive and neg-
ative control protein variants (Fig. 3). When an ex-
tract of 4U105 293 cells was loaded, p53 protein
could not be detected with either the test or the con-
trol antibodies (lanes 8) although 293 cells may ex-
press endogenous p53. A possible explanation is that
p53 is actively degraded in adenovirus infected cells
through a mechanism which involves association
with the large E1B protein [35].
MAb p53-18 was precipitated from the ascites with
ammonium sulfate and was puri¢ed by size-exclusion
chromatography (Fig. 4A). The purity of the anti-
body fractions were analyzed by SDS^PAGE under
reducing conditions. Fig. 4B shows the SDS^PAGE
separated fractions 12^14, containing mAb p53-18,
visualized with Coomassie blue staining. In these
fractions, only two bands, one corresponding to the
heavy chain, and one corresponding to the light
chain could be detected on the gel demonstrating
that mAb p53-18 was separated from other proteins
present in the ascites £uid. The puri¢ed antibody was
used to prepare an a⁄nity column on which murine
p53, expressed in Sf9 insect cells was isolated (Fig. 5).
The fractions eluted with glycine bu¡er pH 2.9 were
analyzed with SDS^PAGE. Staining of the gel with
Coomassie blue evidenced the presence of pure p53
protein in fractions 1^4. These indicate that mAb
p53-18 (unlike some other anti-p53 antibodies) can
be used to speci¢cally detect p53 protein in Western
blots, and immunoa⁄nity columns containing mAb
p53-18 will be able to isolate C-terminally phos-
phorylated p53 originated from various sources.
After puri¢cation of mouse p53 from the recombi-
nant baculovirus infected insect cells, we investigated
whether or not the isolated protein was indeed phos-
phorylated on the PKC site (Ser375) and the CKII
site (Ser389). To this end, the immunoa⁄nity puri-
¢ed p53 protein was subjected to tryptic digestion
and LC-MS. The chromatographic pro¢le obtained
following the tryptic digest showed a typical pattern
of peaks eluting between 10^40 min after application
of the gradient. Location of the anticipated phos-
phorylated peptides is illustrated in Figs. 6 and 7.
Fig. 5. Puri¢cation of murine p53 protein expressed by Sf9 in-
sect cells infected with recombinant baculovirus using mAb
p53-18 a⁄nity column. The fractions from the column were an-
alyzed by SDS^PAGE. The far left lane shows the position of
the molecular mass markers. Lanes 1^8 are the fractions eluted
with the glycine bu¡er, pH 2.9.
Fig. 4. Size-exclusion chromatographic puri¢cation of mAb
p53-18. The ammonium sulfate-precipitated antibody was ap-
plied to a Sepharose S-300 column in PBS (pH 7.6), containing
0.1 M NaCl. (A) Elution pro¢le. Protein peaks were identi¢ed
by an ultraviolet detector operating at 280 nm. (B) The eluted
fractions were analyzed by SDS^PAGE under reducing condi-
tions, and proteins were visualized with Coomassie blue stain-
ing. A set of BioRad prestained molecular mass markers is
found at the far right column.
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These ¢gures show the ultraviolet absorbance pro¢les
and the selective ion pro¢le for m/z 669 correspond-
ing to the singly charged form of the phosphorylated
peptide fragment, Val385^Asp390 (Fig. 6) and the
selective ion pro¢le for m/z 358, corresponding to
the doubly charged form of the phosphorylated pep-
tide fragment, Gly371^Arg376 (Fig. 7). Figs. 8 and 9
illustrate the electrospray ionization mass spectra re-
corded in the chromatographic regions highlighted
by the selective ion pro¢les. Both spectra clearly
identi¢ed the anticipated phosphopeptide signals.
The spectra also contained other major ions which
may be due to additional, closely eluting sample
components. The mass di¡erence between some of
these ions suggests these may be derived from an
ethoxylate polymer, a contaminant often observed
after immunoa⁄nity puri¢cation of proteins.
Similar treatment of the data to try and locate the
corresponding unphosphorylated peptides produced
a selective ion chromatogram for the m/z 635 at
25.4 min (data not shown). As expected based on
earlier phosphopeptide chromatographic studies
[36], this peak eluted later than that of the appropri-
ate phosphopeptide. The mass representing this
HPLC peak was consistent with the singly charged
form of the unphosphorylated peptide fragment
Fig. 6. Ultraviolet absorbance pro¢le (A) and selective ion pro¢le (B) representing the high-performance liquid chromatogram of the
tryptic digest of mouse p53 protein immunopuri¢ed with the p53-18 antibody column. The peak at 23.4 min corresponds to the pep-
tide fragment with a m/z value of 669.
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Gly371^Arg376. Analysis of the data for the other
potential unphosphorylated peptide fragment,
Val385^Asp390, failed to reveal any signi¢cant com-
ponent of this mass. All of these data indicated that
the protein produced by the baculovirus system in
Sf9 insect cells and puri¢ed by using the mAb p53-
18 immunoa⁄nity column was indeed phosphory-
lated at both the PKC and the CKII sites. The sam-
ple submitted to the mass spectroscopy contained
some unphosphorylated version at the PKC site.
This can be potentially due to a smaller amount of
partially phosphorylated protein variant copurifying
with the fully phosphorylated version (compare anti-
body speci¢city with Fig. 1). Another explanation for
the appearance of this unphosphorylated peptide
fragment is phosphate loss during the isolation, di-
gestion and chromatographic processes. Neverthe-
less, the CKII site remained completely phosphory-
lated even after all of these tedious sample
manipulations.
In a separate study, we examined the conforma-
tion and non-sequence speci¢c DNA-binding ability
of our p53 C-terminal peptides and phosphopeptides
[37]. While the peptides are mostly unordered in
Fig. 7. Ultraviolet absorbance pro¢le (A) and selective ion pro¢le (B) representing the high performance liquid chromatogram of the
tryptic digest of mouse p53 protein immunopuri¢ed with the p53-18 antibody column. The peak at 20.9 min corresponds to the pep-
tide fragment with a m/z value of 358.
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water, the unmodi¢ed peptide assumes a relatively
strong K-helix conformation in the structure-induc-
ing solvent TFE. The basic domain is predominantly
unordered in the p53 protein, but it is located prox-
imal to the tetramerization domain (amino acids
319^360; [6]), which forms an anti-parallel four he-
lical bundle, determined by multi-dimensional nu-
clear magnetic resonance studies [7,8]. It is conceiv-
able that the conformational changes in the basic
domain, due to amino acid mutations, will a¡ect
the e⁄ciency of tetramer assembly and function of
p53. In order to determine whether mAb p53-18 saw
a conformation-dependent epitope, we repeated the
ELISA of the unphosphorylated and the double-
phosphorylated 23-mer peptides by using a confor-
mation-sensitive assay protocol. During these assay
conditions, the peptides are applied to the ELISA
plate from TFE, and the antigens are allowed to
dry [31]. The peptides interact with the plastic surface
by exposing new hydrophobic and hydrophilic areas,
and their structure presented by the solvent remains
conserved causing a remarkable variation of peptide
recognition by anti-protein antibodies [31,38]. By us-
ing this ELISA protocol, the diphosphorylated
Fig. 8. Electrospray ionization mass spectrum recorded in the chromatographic region highlighted in Fig. 6. The peak at m/z 669 cor-
responds to the singly charged form of the C-terminal phosphorylated peptide fragment Val385^Asp390. Chromatographic and spec-
troscopic conditions are given in Section 2.
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C-terminal p53 peptide was recognized at high levels
by mAb p53-18, regardless of the secondary structure
of the peptide antigen (Fig. 10). The ‘pro-zone’ bind-
ing behavior indicated optimal antibody^antigen in-
teractions in the entire 0.04^2.5 Wg peptide load
range studied (the dilution of the ascites £uid was
1:1000). In contrast, the unphosphorylated peptide,
unrecognized by the antibody during regular ELISA
conditions, bound to the antibody only when the
peptide was plated from TFE (Fig. 10). Nevertheless,
this induced antibody binding remained at a level
one magnitude below that of the diphosphorylated
analog, and did not show ‘pro-zone’ binding behav-
ior in the studied antigen load range. These ¢ndings
indicate that while the main feature of mAb p53-18
binding to peptide antigens is the presence of phos-
phate groups on Ser378 and Ser392, the antibody is
also sensitive to antigen conformation. Antibody 421
is believed to recognize a linear epitope, and indeed,
its binding to the same unphosphorylated peptide
was neither increased nor signi¢cantly decreased
when the peptide was plated from TFE (OD = 0.18;
data not shown).
Finally, we tested the binding of the synthetic pep-
tides to 40 sera of both cancer patients and healthy
controls. First the sera, in 1:100 and 1:500 dilutions,
Fig. 9. Electrospray ionization mass spectrum recorded in the chromatographic region highlighted in Fig. 7. The peak at m/z 358 cor-
responds to the doubly charged form of the phosphorylated peptide fragment Gly371^Arg376. Chromatographic and spectroscopic
conditions are as described in Section 2.
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were screened against the unphosphorylated, the
Ser378 phosphorylated and the diphosphorylated
23-mer peptides. When the positive sera were identi-
¢ed, the speci¢city of the p53 autoantibodies to the
presence or absence of the C-terminal phosphate
groups was studied by serial dilutions of the sera
(from 1:50 to 1:1500) against peptide antigens dis-
playing all four possible phosphate forms and p53
protein produced in the baculovirus system. After
four repetitions ¢ve sera could be identi¢ed that
clearly bound to at least one of the peptides. From
the ¢ve positive sera, two originated from breast
cancer patients (nos. 7 and 15), two from cervical
cancer patients (nos. 31 and 38), and one from a
healthy control (no. 27). When tested for peptide
speci¢city, all ¢ve sera bound to the double-phos-
phorylated peptide stronger than to any other phos-
phate isoforms (Table 3). The four sera from cancer
patients also recognized the full-sized p53 protein.
The serum from the healthy control subject did not
recognize the p53 protein, indicating that the cross-
reactivity with the double-phosphorylated peptide
was due to unspeci¢c binding, or the epitope for
serum no. 27 was not present in the protein prepa-
ration studied.
4. Discussion
Here we characterized a highly sensitive, multi-
phosphorylation-speci¢c mAb to the C-terminus of
p53. Most recently a pAb, speci¢c to phosphorylated
Ser392 became marketed by New England Biolabs
(Beverly, MA, USA). According to the manufac-
turer, this antibody was obtained by inoculation of
rabbits with a C-terminal phosphopeptide conjugated
to a carrier protein. This pAb is claimed to recognize
p53 only after phosphorylation with CKII at Ser392.
Fig. 10. Conformation-sensitive ELISA of the unphosphory-
lated and diphosphorylated p53 C-terminal peptides. In these
experiments, 40 ng^2.5 Wg amounts of the peptides, dissolved in
either water or TFE, were applied to the plate and dried over-
night. The following day, the plates were blocked with Triton
X-100 and the ELISA was continued by using mAb p53-18 as
the primary antibody. The unphosphorylated peptide is repre-
sented by triangles, and the diphosphorylated peptide is repre-
sented by circles. Open symbols correspond to peptides plated
from water, and closed symbols correspond to peptides plated
from TFE. The dilution of the ascites £uid containing the anti-
body was 1:1000.
Table 3
Speci¢city of autoantibodies in patients’ sera to C-terminal p53 peptides
Serum number and origin Recognition of Speci¢city
p53 371^393 peptides p53 protein
nP 378P 392P 378P, 392P
Positive sera (out of 40)
No. 7; breast cancer 3 + 3 ++ + 378P, (392P)
No. 15; breast cancer 3 þ 3 ++ + 378P, 392P
No. 31; cervical cancer 3 3 3 + + 378P, 392P
No. 38; cervical cancer 3 3 þ + + 378P, 392P
No. 27; healthy control 3 3 3 ++ 3 Nonspeci¢c
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We compared the phosphate speci¢city of this pAb
with our mAb p53-18 against p53 expressed in E. coli
and the protein expressed in Sf9 insect cells infected
by baculovirus, as well as against the four 33-mer
peptides with the di¡erent phosphate forms. In our
hands, the pAb did not recognize the phosphorylated
protein below 1 Wg protein load. Actually, more def-
inite binding was observed against the E. coli ex-
pressed protein up to 0.1 Wg protein load. As a pos-
itive control on the same plate, mAb p53-18 bound
to the p53 variant expressed in the baculovirus sys-
tem more than twice as strongly than it bound to p53
expressed in E. coli, similarly to the pattern depicted
in Fig. 2. At a peptide level, the Ser392 phosphate
speci¢c pAb recognized the Ser392 phosphorylated
and diphosphorylated long peptides weakly at an
antibody dilution of 1:400 (Fig. 11). While complete
loss of binding was observed at higher antibody di-
lutions, at lower dilutions the phosphate speci¢city
seemed to be lost, explaining the detected recognition
of the E. coli expressed protein variant.
Phosphorylation-speci¢c mAbs capable of identify-
ing various phosphate forms of p53 would be espe-
cially attractive in light of a recent report. Whole-cell
proteins from control and apoptotic H460a cells were
separated by two-dimensional electrophoresis and
were transferred to nitrocellulose [39]. As a reporter
antibody, mAb BP53.12 was used to stain the p53
variants. Four isoforms of p53 di¡ering in the phos-
phorylation state, determined by the electrophoretic
mobility di¡erences of the protein variants, could be
detected by mAb BP53.12 in the control cells. Three
additional isoforms were observed to be expressed at
signi¢cant levels only in apoptotic cells [39]. Anti-
body BP53.12 recognizes the N-terminal domain of
p53, where a large number of potential phosphory-
lation sites are found. As the phosphate speci¢city of
this antibody is unknown, it is likely that some im-
portant phosphate forms of the antigens, unrecog-
nized by the antibody, remain undetected in the sys-
tem. Application of our immunization strategy to the
N-terminal regions of p53 is likely to result in phos-
phate-speci¢c mAbs to this domain; experiments
that are currently in progress in our laboratories.
To determine the phosphate speci¢city of mAb
p53-18 at the protein level, we used p53 expressed
in two systems. To increase the production of p53
compared to mammalian tissues and cell lines, p53 is
generally made in bacterial [12], baculovirus [40] and
vaccinia virus [41] expression systems. The protein
produced in E. coli is likely to be unphosphorylated,
or phosphorylated at a low level. Bacterial environ-
ments for phosphorylation usually lack eukaryotic
kinases, and this frequently prevents proper phos-
phorylation from occurring [42]. Indeed, p53 ex-
pressed in E. coli only binds DNA properly after
interaction with cellular proteins, including various
kinases [12]. In contrast, it has been shown that hu-
man p53 expressed in baculovirus-infected Sf9 cells
displays a two-dimensional electrophoretic mobility
pattern (and consequently phosphorylation pattern)
identical to wild-type p53 from human cells [43]. In-
sect cells appear to contain all protein kinases neces-
sary for phosphorylation of a mammalian protein
[44], with at least nine potential p53 sites phosphory-
lated in this system [43]. Accordingly, our murine
p53 originated from the Sf9 cells was expected to
carry phosphate groups on both Ser375 and
Ser389. Nevertheless, it is assumed that phosphory-
lation of p53 in the baculovirus system is heteroge-
neous [44], thus reducing the level of recognition by
mAb p53-18 and allowing binding of pAb 421 [43].
Our LC^MS of the tryptic digest of mouse p53 pro-
Fig. 11. Phosphate speci¢city of a pAb marketed by New Eng-
land Biolabs (Beverly, MA, USA). The pAb in various dilutions
was probed against the four 33-mer peptides: open triangles
and dots, unphosphorylated peptide; open circles and dashes,
peptide phosphorylated on Ser378; open squares and dots and
dashes, peptide phosphorylated on Ser392; full triangles and
solid line, peptide phosphorylated on both Ser378 and Ser392.
Conventional ELISA conditions were used.
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duced by the baculovirus system clearly showed the
presence of phosphate groups on both the PKC and
the CKII sites. The highly discriminative properties
of our mAb p53-18 towards the phosphorylation sta-
tus of p53 will make this reagent suitable not only to
detect low levels of phosphorylated p53, but in com-
bination with other currently available antibodies, to
estimate the actual degree of phosphorylation in the
cell lines and tissues studied.
A recent report voiced concerns about the quality
of anti-p53 antibodies [45]. According to this paper,
immunohistochemical staining of tissue sections
show remarkable di¡erences when using di¡erent
batches of pAb 421. Moreover, antibody 1801 from
one source recognizes proteins in cell lines di¡erently
than the same antibody does that is obtained from
another manufacturer [45]. These ¢ndings underline
the importance of the thorough characterization of
the anti-p53 antibodies. Here we described the anti-
gen speci¢city of our mAb p53-18 in details unsur-
passed in the current literature. However, the protein
variants themselves often exhibit considerable vari-
ability. In the current paper, we presented our ¢nd-
ings by using recombinant p53 produced by E. coli,
puri¢ed by a metal-chelating column. We claim that
this protein variant is unphosphorylated, or phos-
phorylated to a very low degree, as are most proteins
obtained from bacterial sources. mAb p53-18 did not
recognize this protein when we followed the ELISA
protocol suitable for antibodies of the IgM isotype,
and this ¢nding mirrored those by using the unphos-
phorylated synthetic peptide. However, the antibody
cross-reacted with another E. coli-produced p53
preparation, puri¢ed from bacterial lysates by gluta-
thione agarose a⁄nity chromatography (marketed by
Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Here we would like to draw the attention of the
variability of the currently studied protein prepara-
tions, and appeal for the thorough characterization
not only of the antibodies but also of the distributed
antigens. In this regard, fully puri¢ed synthetic pep-
tides can be considered as reagents of signi¢cant util-
ity.
Autoantibodies to p53 in humans, mostly in can-
cer patients, preferentially recognized the double-
phosphorylated peptide. Considering the relatively
large distance of 14 amino acid residues between
the two phosphate groups, it is reasonable to sup-
pose that those three-dimensional structure variants
of the protein, and perhaps of the peptide, in which
phosphorylated Ser378 and Ser392 are close to each
other in space, preferentially populate the conforma-
tional equilibria. This logic bestows a conformational
nature on the epitope recognized by the anti-p53 C-
terminal antibodies. In support of this, when the un-
phosphorylated peptide was forced to assume a more
ordered structure of an K-helix it became recogniz-
able by mAb p53-18. A helical wheel projection of
the short peptide places Ser378 and Ser392 very close
to each other (Fig. 12). In this regard, TFE might
mimic a structure of the unphosphorylated antigen
closer to the native conformation of the diphos-
phorylated peptide. Nevertheless, the two structures
are clearly di¡erent as we demonstrated a helix-
breaking e¡ect of phosphorylation (by using the
33-mer p53 C-terminal peptide) by circular dichroism
and nuclear magnetic resonance spectroscopy [37].
This structural di¡erence and the requirement for
the phosphate group on the antigen for the recogni-
tion by mAb p53-18 is evident from the markedly
decreased antibody binding to the unphosphorylated
peptide even when both antigens were plated from
TFE. Moreover, the unphosphorylated protein was
not recognized, indicating that the very C-terminus
of p53 does not populate K-helices. This is in accord-
ance with the general expectations of conformational
preferences (actually the lack thereof) of extreme ter-
mini of proteins and circular dichroism studies of a
large C-terminal synthetic fragment of p53 [46].
Fig. 12. Helical wheel representation of the structure of p53
peptide 371^393. The inner circle corresponds to the ¢rst 18
amino acids, and the outer circle corresponds to amino acids
19^23, overlapping amino acids 1^5. Ser378 (in position 8) and
Ser392 (at the outer circle in position 4) are marked with aster-
isks.
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mAb p53-18 recognized both human and
mouse p53 proteins. The di¡erences between the
C-terminal 23-mer human and mouse sequences are
as follows: S371T, L383T, F385V, T387K and
E388V. Careful examination of the sequences reveals
no mutation within a 3 amino acid-distance from
either phosphorylation site (Ser378 or Ser392). The
unchanged primary structure around the phosphor-
ylation sites explains the cross-reactivity of the anti-
body.
mAb p53-18 was obtained after immunization with
the diphosphorylated C-terminal p53 peptide. Our
original research plan was to select antibodies specif-
ic for either phosphate forms. An exhaustive analysis
of the generated antibodies, however, revealed the
complete lack of antibodies speci¢c for Ser378 or
Ser392 only. It appears that only the multiphos-
phorylated form of the C-terminal p53 domain is
immunogenic enough to produce highly sensitive
antibodies. This is not particularly surprising if we
look at the analogy with the human d protein. Ab-
normally hyperphosphorylated variants of the low
molecular weight microtubule-associated protein d
are the main proteinaceous constituents of the paired
helical ¢laments (PHF) of Alzheimer’s disease [47].
PHF-d carrying phosphate groups on nearby serines
and threonines are highly immunogenic structures
inasmuch as many anti-PHF antibodies, and all truly
speci¢c for the disease-related forms of d, recognize
multiphosphorylated antigens both at the peptide
and the protein levels [38]. When mice were immu-
nized with a chimeric 31D-multiphosphorylated d
peptide complex, the obtained sera were highly spe-
ci¢c for the diphosphorylated antigen [48]. This ob-
servation further supports the idea that it is the
extended presence of the protease-resistant multi-
phosphorylated immunogens that can turn otherwise
poorly immunogenic structures to highly immuno-
genic ones.
Phosphorylation of p53 at Ser392 appears neces-
sary for tumor suppressor function since substitution
with alanine abolishes the ability of p53 to suppress
cell proliferation, whereas substitution with aspartic
acid, which mimics phosphoserine, has only a partial
e¡ect on p53-mediated growth inhibition [49]. The
suppressor function is a highly controversial issue.
A recent paper claims that individual mutations of
the N-terminal serines, as well as Ser315 and Ser392
to alanine or glutamic acid result in equivalent levels
of transcriptional activation in standard transient
transfection experiments [50]. However, when p53’s
transcriptional activation is measured in cells that
attain G1 arrest upon contact inhibition, wild-type
p53 is inactive, and only altering Ser392 to glutamic
acid results in a functional protein. This Ser^Glu
mutant also has an increased ability to bind DNA
[50]. On the other hand, Fiscella and coworkers [51]
reported that elimination of the Ser392 phosphoryla-
tion site has no discernible e¡ect on p53 function,
and phosphorylation is also reported not to a¡ect
the tetramerization of p53 [52]. Again, in contrast,
most recent equilibrium ultracentrifugal analyses
showed that phosphorylation of Ser392 increases
the association constant for reversible tetramer for-
mation nearly 10-fold [53]. The actual level of phos-
phorylation of the C-terminal sites are questionable
because both PKC [54,55] and CKII [56,57] have to
be translocated from the cytosol to the nucleus to
actively phosphorylate p53. This gives rise to a pos-
sible di¡erence between the status of phosphoryla-
tion in healthy or cancerous cells. Actually, murine
equivalents of Ser371, Ser376, Thr377, and Ser378 of
human p53 all can be phosphorylated by PKC in
vitro, but loss of the pAb 421 epitope could not be
detected in the cells suggesting that p53 and PKC
may not interact at all in vivo [58]. Many of these
controversies can be solved by measuring the binding
of mAb p53-18 to p53 variants in di¡erent cell com-
partments, cell types, and disease states.
In summary, here we described a novel phosphate-
speci¢c mAb to p53. This antibody bears the promise
to be a highly useful biochemical marker to detect
low levels of p53 protein in di¡erent tissues, and to
be a key tool to characterize the status of phosphor-
ylation of the C-terminus of p53 protein in various
cell types, solution environments and stages of tumor
progression.
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